Digital health company ResApp Health (ASX:RAP) has agreed to a 12-month extension to its commercial licence agreement with Medgate.
Under the agreement, Medgate uses ResApp’s smartphone-based acute respiratory diagnostic test, ResAppDx, on its telehealth platform.
Medgate is a leading provider of telehealth services and since 2000 has operated the largest telemedical centre run by doctors in Europe. The group employs over 510 people worldwide, including over 200 physicians.
ResApp’s acute respiratory diagnostic test, ResAppDx, uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s inbuilt microphone.
ResAppDx is CE Marked in Europe and TGA-approved in Australia.
ResApp CEO and managing director Dr Tony Keating said, “Medgate is a long-standing, global leader in telehealth and we are proud to extend our commercial licence agreement. It’s pleasing to see that Medgate extending the use of ResAppDx to additional patient journeys for the benefit of more patients and clinicians. We believe this is further strong endorsement of the value of ResAppDx to patients, clinicians and telehealth providers.”
Medgate CEO Dr Andy Fischer added, “ResApp continues to be an exemplary partner and over the course of the last 12 months we’ve built further evidence of the benefits of ResAppDx to our clinicians and patients. We look forward to expanding our use of ResAppDx to further realise these benefits for our patients. Our intention is to be the most innovative leader in the global telehealth market and the adoption of ResApp’s AI plays an important role in helping us to achieve this by transforming the patient journey.”